Press release
Investigation announced for Investors in shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) over potential Wrongdoing
An investigation on behalf of investors in Fennec Pharmaceuticals Inc. (NASDAQ: FENC) shares over potential wrongdoing.
Investors who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Fennec Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders.
North Carolina based Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States.
On November 29, 2021, Fennec Pharmaceuticals Inc. (NASDAQ: FENC) that “. . . it expects the U.S. Food and Drug Administration will not accept the company’s New Drug Application for PEDMARK™.”
Fennec Pharmaceuticals Inc. also stated that “. . . it expects to receive a Complete Response Letter (CRL) after the PDUFA target action date of November 27, 2021 from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for PEDMARKTM (a unique formulation of sodium thiosulfate), for intravenous administration for the prevention of ototoxicity associated with cisplatin chemotherapy in pediatric patients ≥1 month to 18 years of age with localized, non-metastatic, solid tumors.”
Further, Fennec Pharmaceuticals Inc. reported that “[t]he FDA has indicated that, following a recent completion of a pre-approval inspection of the manufacturing facility of our drug product manufacturer, deficiencies have been identified.”
Shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) declined from $10.05 per share on November 23, 2021, to as low as $3.822 per share on December 1, 2021.
Those who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) over potential Wrongdoing here
News-ID: 2540315 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Fennec
Hepatoblastoma Market Growing Rapidly by - Eureka Therapeutics, Fennec Pharmaceu …
DataM Intelligence has published a new research report on "Hepatoblastoma Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/hepatoblastoma-market
The…
Investigation announced for Long-Term Investor in shares of Fennec Pharmaceutica …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Fennec Pharmaceuticals Inc..
Investors who are current long term investors in Fennec Pharmaceuticals Inc. (NASDAQ: FENC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: FENC stocks follows a lawsuit filed against Fennec…
Deadline on April 11th coming up in Lawsuit for Investors in Fennec Pharmaceutic …
A deadline is coming up on April 11, 2022 in the lawsuit filed for certain investors of Fennec Pharmaceuticals Inc. (NASDAQ: FENC).
Investors who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and there are strict and short deadlines running. Deadline: April 11, 2022. NASDAQ: FENC stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S.…
Lawsuit filed for Investors in shares of Fennec Pharmaceuticals Inc. (NASDAQ: FE …
An investor, who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC), filed a lawsuit over alleged Securities Laws violations by Fennec Pharmaceuticals Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and for certain investors are short and strict deadlines running. Deadline: April 11, 2022. NASDAQ: FENC investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call…
Investigation announced for Long-Term Investors in shares of Fennec Pharmaceutic …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Fennec Pharmaceuticals Inc..
Investors who are current long term investors in Fennec Pharmaceuticals Inc. (NASDAQ: FENC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: FENC stocks follows a lawsuit filed against Fennec Pharmaceuticals Inc…
Lawsuit filed for Investors in shares of Fennec Pharmaceuticals Inc. (NASDAQ: FE …
An investor, who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC), filed a lawsuit over alleged violations of Federal Securities Laws by Fennec Pharmaceuticals Inc.
Investors who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and for certain investors are short and strict deadlines running. Deadline: November 02, 2020. NASDAQ: FENC investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On August 11,…
